Physician
Hematology
Dr. Gauri R. Varadhachary, MD
|
|
Give Review
Gauri Varadhachary is an expert in the field of Hematology. She graduated from L. Tilak Municipal Medical College. She received awards:"America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Gauri R. Varadhachary is a published doctor. She published 83 publications, including: 'Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Che...' She accepts Medicare.
Publications
- Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic Cancer.
- Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
- Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DuctAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.
- Occult primary, version 3.2014.
- Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.
- Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic Cancer?
- Resectable, borderline resectable, and locally advanced pancreatic Cancer: what does it matter?
- CT imaging features of acinar cell carcinoma and its hepatic metastases.
- Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic Ductal adenoca...
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival.
- Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification.
- Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer.
- Rational Study Endpoint(s) for Preoperative Trials in Pancreatic Cancer: Pathologic Response Rate, Margin Negative Resection, Overall Survival or 'All of the Above'?
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic Cancer.
- Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.
- The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic Cancer.
- New Strategies for Carcinoma of Unknown Primary: the role of tissue of origin molecular profiling.
- The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma.
- Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis.
- Cost-effectiveness of treatment strategies for Pancreatic head adenocarcinoma and potential opportunities for improvement.
- Carcinoid tumours: predicting the location of the primary Neoplasm based on the sites of metastases.
- Yield of clinical and radiographic surveillance in patients with resected Pancreatic adenocarcinoma following multimodal therapy.
- Response of borderline resectable pancreatic Cancer to neoadjuvant therapy is not reflected by radiographic indicators.
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy.
- A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
- Histologic tumor involvement of superior mesenteric Vein/portal Vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuva...
- Carcinoma of unknown primary: focused evaluation.
- Occult primary.
- Pathologic complete response to neoadjuvant therapy in patients with pancreatic Ductal adenocarcinoma is associated with a better prognosis.
- Histologic grading the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic Ductal adenocarcinoma: A predictor for patient outcome.
- Preoperative therapies for resectable and borderline resectable pancreatic Cancer.
- Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases.
- Post-therapy pathologic stage and survival in patients with pancreatic Ductal adenocarcinoma treated with neoadjuvant chemoradiation.
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of...
- Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis.
- Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary.
- Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic Cancer: a phase II trial.
- The war on pancreatic Cancer: are we gaining ground?
- Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic Cancer treated with neoadjuvant chemoradiation.
- Challenges in the study of adjuvant chemoradiation after Pancreaticoduodenectomy.
- A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic Cancer.
- Gene expression profiling in Cancers of unknown primary.
- Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
- Overview of patient management and future directions in unknown primary carcinoma.
- Novel approaches to 'borderline resectable' pancreatic Tumors.
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic Cancer.
- Adjuvant therapy for adenocarcinoma of the pancreas: Analysis of reported trials and recommendations for future progress.
- Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
- Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the Pancreatic head.
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the Pancreatic head.
- Borderline resectable pancreatic Cancer: the importance of this emerging stage of disease.
- Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and Ovarian metastases.
- Carcinoma of unknown primary origin.
- Current management of borderline-resectable pancreatic Cancer.
- Induction chemotherapy selects patients with locally advanced, unresectable pancreatic Cancer for optimal benefit from consolidative chemoradiation therapy.
- Delayed recovery after pancreaticoduodenectomy: a major factor impairing the deLivery of adjuvant therapy?
- Borderline resectable pancreatic Cancer: definitions, management, and role of preoperative therapy.
- Phase I trial of oral talactoferrin alfa in refractory solid Tumors.
- Metastatic patterns in adenocarcinoma.
- Front-line therapy for advanced coloRectal cancer: emphasis on chemotherapy.
- Borderline resectable pancreatic Cancer.
- Diagnostic strategies for unknown primary Cancer.
- Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic Cancer.
- Carcinoma of unknown primary with a colon-Cancer profile-changing paradigm and emerging definitions.
- Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.
- The integration of chemoradiation in the care of patient with localized pancreatic Cancer.
- Spontaneous pneumothorax in malignancy: a case report and review of the literature.
- Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes.
- Long-term survival after multidisciplinary management of resected Pancreatic adenocarcinoma.
- Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer.
- Molecular profiling for CUP Cancers: are we there yet?
- Gastric adenocarcinoma in children and adolescents.
- Future chemoradiation strategies in pancreatic Cancer.
- Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
- Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid Tumors.
- Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial.
- Prognostic factors in patients with unresectable locally advanced Pancreatic adenocarcinoma treated with chemoradiation.
- Patterns of self-reported symptoms in pancreatic Cancer patients receiving chemoradiation.
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid Tumors.
- The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic Cancer.
- Preoperative and adjuvant therapies for upper gastrointestinal Cancers.
- Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Che...
Schools
UNIVERSITY OF BOMBAY LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE
Greater Baltimore Med Center
Baylor
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
L. Tilak Municipal Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1417980442 | |
| NPPES Provider LastName | VARADHACHARY | |
| NPPES Provider FirstName | GAURI | |
| NPPES Provider ZIPCode | 770303000 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 350.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 48.0 | |
| Percent Opioid Claims | 13.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417980442 |
| Last Name Of The Provider | VARADHACHARY |
| First Name Of The Provider | GAURI |
| View All |
Similar Doctors
|
|
Dr. Modupe Idowu, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Krishna K. Pachipala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanam Loghavi, MD |
|
|
Dr. Faheem Ahmed, MD |
|
|
Dr. Michael H. Kroll, MD |
|
|
Dr. Leonard A. Zwelling, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rammurti T. Kamble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pei Lin, MD |